KEYNOTE-045: 5-Yr Follow-up of Pembrolizumab in Recurrent Advanced Urothelial Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
With a median follow-up of 5 years, pembrolizumab continued to show improved overall survival compared with investigator’s choice of chemotherapy in patients with recurrent advanced urothelial cancer on the KEYNOTE-045 trial.
Format: Microsoft PowerPoint (.ppt)
File Size: 467 KB
Released: June 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Exelixis
Merck Sharp & Dohme Corp.

Related Content

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with nmCRPC.

David F. Penson, MD Released: September 10, 2021

Slides from Clinical Care Options (CCO) on best practices in classifying prostate cancer and using ADT

Daniel W. Lin, MD Released: September 10, 2021

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with mHSPC.

Alicia K. Morgans, MD, MPH Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue